Search: WFRF:(Sjoberg Daniel) > Value of Intact Pro...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04544naa a2200493 4500 | |
001 | oai:lup.lub.lu.se:7ddd135a-a5c5-4567-b928-0f893035e0ae | |
003 | SwePub | |
008 | 180507s2018 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/7ddd135a-a5c5-4567-b928-0f893035e0ae2 URI |
024 | 7 | a https://doi.org/10.1016/j.juro.2018.01.0702 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Vickers, Andrewu Memorial Sloan-Kettering Cancer Center4 aut |
245 | 1 0 | a Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model : An Individual Patient Data Meta-Analysis |
264 | 1 | b Ovid Technologies (Wolters Kluwer Health),c 2018 |
520 | a Purpose: The 4 kallikrein panel, commercially available as the 4Kscore®, is a statistical model that has been shown to accurately predict Gleason Grade Group 2 or greater (high grade) cancer on biopsy and the long-term risk of distant prostate cancer metastases. The panel includes 2 novel markers, namely intact prostate specific antigen and hK2. It has been questioned whether these 2 additional markers add discrimination to the clinical predictors of patient age, digital rectal examination and prior biopsy, and the established molecular markers total and free prostate specific antigen. Materials and Methods: We performed an individual patient data meta-analysis of published studies in which the 4 kallikrein panel was measured in men undergoing prostate biopsy. We assess the improvement in discrimination associated with including intact prostate specific antigen and hK2 along with total and free prostate specific antigen in the statistical model. Results: Included in analysis were 14,510 men from a total of 10 studies. The fixed effects meta-analytical estimate of the discrimination of the model without intact prostate specific antigen and hK2 was 0.742 (95% CI 0.727–0.756) compared to 0.813 (95% CI 0.801–0.825) for the full kallikrein model. The 95% CIs did not overlap and the difference in discrimination was highly statistically significant (0.069, 95% CI 0.057–0.080, p <0.0001). Intact prostate specific antigen (increase in discrimination 0.059, 95% CI 0.050–0.069) and hK2 (increase in discrimination 0.024, 95% CI 0.020–0.029, each p <0.0001) added independently to the model. Conclusions: The clinical value of the panel could not be replicated using data readily available to urologists without measuring intact prostate specific antigen and hK2. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a digital rectal examination | |
653 | a early detection of cancer | |
653 | a kallikreins | |
653 | a prostate-specific antigen | |
653 | a prostatic neoplasms | |
700 | 1 | a Vertosick, Emily A.u Memorial Sloan-Kettering Cancer Center4 aut |
700 | 1 | a Sjoberg, Daniel D.u Memorial Sloan-Kettering Cancer Center4 aut |
700 | 1 | a Hamdy, Freddieu University of Oxford4 aut |
700 | 1 | a Neal, Davidu University of Oxford4 aut |
700 | 1 | a Bjartell, Andersu Lund University,Lunds universitet,Urologisk cancerforskning, Malmö,Forskargrupper vid Lunds universitet,Urological cancer, Malmö,Lund University Research Groups4 aut0 (Swepub:lu)kir-abj |
700 | 1 | a Hugosson, Jonasu University of Gothenburg4 aut |
700 | 1 | a Donovan, Jenny L.u University of Bristol4 aut |
700 | 1 | a Villers, Arnauldu Lille 2 University4 aut |
700 | 1 | a Zappala, Stephenu Andover Urology4 aut |
700 | 1 | a Lilja, Hansu Memorial Sloan-Kettering Cancer Center4 aut0 (Swepub:lu)klke-hli |
710 | 2 | a Memorial Sloan-Kettering Cancer Centerb University of Oxford4 org |
773 | 0 | t Journal of Urologyd : Ovid Technologies (Wolters Kluwer Health)g 199:6, s. 1470-1474q 199:6<1470-1474x 0022-5347x 1527-3792 |
856 | 4 | u http://dx.doi.org/10.1016/j.juro.2018.01.070y FULLTEXT |
856 | 4 | u https://europepmc.org/articles/pmc6596413?pdf=render |
856 | 4 8 | u https://lup.lub.lu.se/record/7ddd135a-a5c5-4567-b928-0f893035e0ae |
856 | 4 8 | u https://doi.org/10.1016/j.juro.2018.01.070 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.